On Monday, Barclays issued a downgrade for DuPont (NYSE:DD) stock from Equalweight to Underweight, adjusting the price target to $84 from $88. The firm's analysis suggests that the potential benefits of DuPont's breakup are already reflected in the current stock price, leaving little room for additional gains.
The downgrade is based on a sum-of-the-parts evaluation, which indicates the high valuation multiples for DuPont's segments in Water, Electronics, and the remaining industrial businesses may not be sustainable.
The firm points out that while these segments are currently assigned high multiples similar to pure-play companies, it's uncertain whether DuPont's spin-off entities will immediately warrant such valuations.
According to Barclays, the segments in question are often compared to companies with multiples around 20 times the next twelve months (NTM) consensus EBITDA for Water and Electronics, and approximately 15 times for the remaining industrial companies.
However, differences in top-line growth, earnings volatility, and cash conversion rates, as well as potential liabilities related to PFAS, are factors that could impact these valuations.
The firm also expresses skepticism regarding the potential re-rating of the RemainCo DuPont, which is expected to spin off its two higher-multiple businesses. These segments represent about half of DuPont's current earnings. Historically, RemainCo has traded at approximately 11 to 12 times for the past three years, and the firm questions whether a higher valuation is justified post-spinoff.
In summary, Barclays' downgrade reflects concerns over DuPont's future earnings multiples and the potential undervaluation of risks associated with the company's business segments and liabilities. The new price target of $84 reflects these considerations and suggests a more cautious outlook for the stock.
In other recent news, DuPont has made significant strides in its operations and financial health. The company recently completed a major expansion at its Sasakami Site in Japan, nearly doubling its photoresist manufacturing capacity. This development is aimed at meeting the rising global demand for photoresists, essential materials used in semiconductor manufacturing.
Additionally, DuPont reported robust second-quarter earnings that surpassed market expectations, leading to an upward revision of its financial forecasts. The company also reported a 17% increase in operating EBITDA for Q2 2024, attributed to advancements in AI and a resurgence in the consumer electronics market.
In the analyst realm, RBC Capital, JPMorgan, and BMO Capital Markets have all revised their price targets for DuPont, maintaining positive ratings due to the company's solid financial position and promising growth trajectory. DuPont's margin expansion, cost savings, and volume recovery were noted as key contributors to its strong performance.
Recent developments include DuPont's acquisition of Donatelle to strengthen its foothold in the medical device sector. Regarding PFAS liabilities, DuPont is nearing settlement, which will reduce legal and financial uncertainties. These recent developments, coupled with the company's strategic initiatives and strong balance sheet, indicate a promising outlook for DuPont.
InvestingPro Insights
While Barclays has downgraded DuPont, citing concerns over valuation multiples and potential risks, recent data from InvestingPro offers additional context for investors. DuPont's current P/E ratio stands at 56.57, which aligns with Barclays' observation of high valuation multiples. However, the company's adjusted P/E ratio for the last twelve months as of Q2 2024 is lower at 49.79, suggesting some potential for value when accounting for adjustments.
InvestingPro Tips highlight that DuPont has maintained dividend payments for 54 consecutive years, demonstrating a strong commitment to shareholder returns. This consistency could be appealing to income-focused investors, especially given the current dividend yield of 1.74%. Additionally, the company's liquid assets exceed short-term obligations, indicating a solid financial position that may provide some cushion against the concerns raised by Barclays.
It's worth noting that DuPont is trading near its 52-week high, with the stock price at 97.2% of its peak. This strength in share price, combined with analysts' expectations of profitability this year, suggests that market sentiment remains positive despite the downgrade.
For investors seeking a more comprehensive analysis, InvestingPro offers 10 additional tips for DuPont, providing a broader perspective on the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.